Illumina, Inc. has announced that in collaboration with a prominent pharmaceutical company, the Genome Institute of Singapore (GIS) will utilize the HumanRef-8 Expression BeadChip to analyze up to 3,000 samples.
The GIS is a flagship facility in Singapore that pursues the integration of technology, genetics and biology towards the goal of individualized medicine.
"We are excited to see distinguished institutions adopt the value proposition of gene expression platforms such as the Genome Institute of Singapore," said Jay Flatley, Illumina President and Chief Executive Officer.
"This collaboration, combined with agreements earlier in the year with other top pharmaceutical companies demonstrates our success and progress in this important market segment."
"Illumina has become a choice microarray platform at our institute. The HumanRef-8 is to date unparalleled based on technical performance, quality of content, and value," said Lance D. Miller, PhD, Senior Group Leader of Microarray and Expression Genomics at the Genome Institute of Singapore.
"I particularly like that the BeadChips are all from the same beadpool. With a sample size of nearly 3,000 this is important for generating uniform data - free of the technical noise associated with batch-to-batch variation that plagues other platforms."